Shaf Keshavjee

UTHealth Surgeons at Memorial Hermann First in Texas to Perform Double Lung Transplant On Patient Whose Lungs Were Damaged By COVID-19

Thursday, September 17, 2020 - 12:18am

HOUSTON, Sept. 16, 2020 /PRNewswire/ --UTHealthtransplant surgeons at Memorial Hermann were the first in Texas to perform a double lung transplant on a 70-year-old man whose lungs were severely damaged by COVID-19.

Key Points: 
  • HOUSTON, Sept. 16, 2020 /PRNewswire/ --UTHealthtransplant surgeons at Memorial Hermann were the first in Texas to perform a double lung transplant on a 70-year-old man whose lungs were severely damaged by COVID-19.
  • "At that point, we determined that the only way he would survive was if he underwent a double lung transplant."
  • More than 2,700 lung transplants were performed in the United States in 2019 and approximately two-thirds of those were double lung transplants.
  • Jyothula said that patients survive longer when receiving a double lung transplant as opposed to a single lung transplant.

TransMedics to Report First Quarter 2020 Financial Results on May 6, 2020

Thursday, April 23, 2020 - 9:05pm

ANDOVER, Mass., April 23, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (TransMedics) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter after market close on Wednesday, May 6, 2020.

Key Points: 
  • ANDOVER, Mass., April 23, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (TransMedics) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter after market close on Wednesday, May 6, 2020.
  • The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m.
  • A live and archived webcast of the event will be available on the Investors section of the TransMedics website at www.transmedics.com .
  • TransMedics is the worlds leader in portable ex-vivo warm perfusion and assessment of donor organs for transplantation.

JHLT releases first reports of heart transplant recipients infected with COVID-19

Wednesday, March 18, 2020 - 4:42pm

ADDISON, Texas, March 18, 2020 (GLOBE NEWSWIRE) -- The Journal of Heart and Lung Transplantationreleased the first report examining the impact of COVID-19 on two heart transplant recipients who contracted the virus in their native China.

Key Points: 
  • ADDISON, Texas, March 18, 2020 (GLOBE NEWSWIRE) -- The Journal of Heart and Lung Transplantationreleased the first report examining the impact of COVID-19 on two heart transplant recipients who contracted the virus in their native China.
  • The two patients presented with varied levels of severity -- one mild, the other more severe and requiring prolonged hospitalization.
  • Well need to study a broader pool of patients, but its possible that, among heart transplant recipients, the anti-inflammatory effects of immunosuppression actually lessen the expression of COVID-19 into its severe stages, said Dr. Mehra.
  • It is unknown if heart transplant recipients have differential expression of pulmonary ACE-2, since a lower expression may result in less severe illness.

TransMedics to Report Fourth Quarter and Full Year 2019 Financial Results on March 2, 2020

Wednesday, February 19, 2020 - 9:05pm

ANDOVER, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (TransMedics) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2019 after market close on Monday, March 2, 2020.

Key Points: 
  • ANDOVER, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (TransMedics) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2019 after market close on Monday, March 2, 2020.
  • The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m.
  • A live and archived webcast of the event will be available on the Investors section of the TransMedics website at www.transmedics.com .
  • TransMedics is the worlds leader in portable ex-vivo warm perfusion and assessment of donor organs for transplantation.

TransMedics to Present at the 38th Annual J.P. Morgan Healthcare Conference

Thursday, December 19, 2019 - 1:00pm

ANDOVER, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (TransMedics) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced the company will present at the upcoming 38th Annual J.P. Morgan Healthcare Conference in San Francisco.

Key Points: 
  • ANDOVER, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (TransMedics) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced the company will present at the upcoming 38th Annual J.P. Morgan Healthcare Conference in San Francisco.
  • TransMedics management is scheduled to present on Wednesday, January 15, 2020 at 3:30 p.m. Pacific Time.
  • A live and archived webcast of the presentation and breakout session will be available on the Investors section of the TransMedics website at www.transmedics.com .
  • TransMedics is the worlds leader in portable ex-vivo warm perfusion and assessment of donor organs for transplantation.

TransMedics to Report Third Quarter 2019 Financial Results on November 6, 2019

Wednesday, October 16, 2019 - 9:05pm

ANDOVER, Mass., Oct. 16, 2019 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (TransMedics) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter of 2019 after market close on Wednesday, November 6, 2019.

Key Points: 
  • ANDOVER, Mass., Oct. 16, 2019 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (TransMedics) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter of 2019 after market close on Wednesday, November 6, 2019.
  • The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m.
  • A live and archived webcast of the event will be available on the Investors section of the TransMedics website at www.transmedics.com .
  • TransMedics is the worlds leader in portable ex-vivo warm perfusion and assessment of donor organs for transplantation.

UHN and SQI Diagnostics Successfully Test New Technology to Assess Lung Health During Transplant

Tuesday, June 18, 2019 - 2:00pm

TORONTO, June 18, 2019 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company"), University Health Network (UHN) together with its partner SQI Diagnostics Inc. have performed the first successful tests of a groundbreaking procedure that reduces the time to assess lung health from over three hours to less than 50 minutes.

Key Points: 
  • TORONTO, June 18, 2019 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company"), University Health Network (UHN) together with its partner SQI Diagnostics Inc. have performed the first successful tests of a groundbreaking procedure that reduces the time to assess lung health from over three hours to less than 50 minutes.
  • "Integrating rapid diagnostics gives transplant teams the means to more accurately assess the health of donor lungs," said Dr. Shaf Keshavjee, Director, Toronto Lung Transplant Program.
  • The TORdx LUNG is a proprietary research-use assay co-developed by the Toronto Lung Transplant Program at UHN and life sciences and diagnostic company SQI Diagnostics.
  • The assay gives transplant surgeons an indication of lung health by measuring certain biomarkers of the donor organ throughout the lung transplantation procedure.

Loyola Medicine Performs Its 1,000th Lung Transplant

Thursday, May 16, 2019 - 11:01pm

MAYWOOD, Ill., May 16, 2019 /PRNewswire/ --Loyola Medicine's groundbreaking lung transplant program has reached a major new milestone by performing its 1,000th lung transplant.

Key Points: 
  • MAYWOOD, Ill., May 16, 2019 /PRNewswire/ --Loyola Medicine's groundbreaking lung transplant program has reached a major new milestone by performing its 1,000th lung transplant.
  • Since establishing the first lung transplant program in Illinois, Loyola has performed more than twice as many lung transplants as all other transplant centers in the state combined.
  • Jeffrey Schwartz, MD, surgical director of lung transplantation, said Loyola's 1,000th lung transplant "is a testament to the hard work and dedication of our entire multidisciplinary lung transplant team."
  • Loyola Medicine regularly evaluates and successfully performs the most challenging lung transplant cases, including patients who have been turned down by other centers.

SQI partners with Toronto's University Health Network on multiplexed testing to improve the success of organ transplantation

Monday, February 4, 2019 - 2:00pm

SQI is a Toronto-based life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced multiplexed diagnostics.

Key Points: 
  • SQI is a Toronto-based life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced multiplexed diagnostics.
  • SQI scientists will work with Dr. Shaf Keshavjee who heads the world-renowned Toronto Lung Transplant Program at UHN and the University of Toronto.
  • A significant challenge exists to assess the quality and health of a donor lung and the suitability for transplantation.
  • "We are pleased to work with SQI, another Canadian pioneer, in advancing health care through leading edge diagnostic advances."

Glyn R. Morgan, MD, Named Director Of Loyola Medicine's Division Of Intra-Abdominal Transplant

Thursday, October 25, 2018 - 11:04pm

MAYWOOD, Ill., Oct. 25, 2018 /PRNewswire/ --Glyn R. Morgan, MD, MSc, FRCSC, FACS, one of the nation's leading liver and kidney transplant surgeons, has been named director of Loyola Medicine's division of intra-abdominal transplant.

Key Points: 
  • MAYWOOD, Ill., Oct. 25, 2018 /PRNewswire/ --Glyn R. Morgan, MD, MSc, FRCSC, FACS, one of the nation's leading liver and kidney transplant surgeons, has been named director of Loyola Medicine's division of intra-abdominal transplant.
  • Before joining Loyola, Dr. Morgan was director of liver transplantation at the NYU Langone Transplant Institute in New York City, where he co-founded the NYU living donor liver transplant program.
  • Dr. Morgan earned his MD and MSc degrees from the University of Toronto, where he also completed a residency in surgery.
  • Dr. Morgan is a professor in the department of surgery of Loyola University Chicago Stritch School of Medicine.